Medicamen Biotech's Stock Hits 52-Week Low, Given 'Sell' Call by MarketsMOJO

Mar 05 2024 10:05 AM IST
share
Share Via
Medicamen Biotech, a microcap pharmaceutical company, has recently hit a 52-week low on March 5th, 2024, with a current stock price of 0.99% away from its low. According to MarketsMojo, the stock has been given a 'Sell' call and has underperformed the sector by -0.85% in today's trading session. The stock has been on a downward trend for the past 3 days, with a -3.31% fall in returns. Additionally, the company's stock is currently trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend. In comparison to the Sensex, Medicamen Biotech has significantly underperformed in the last year, with a -28.36% performance while the Sensex has seen a growth of 23.06%. As a microcap company, investors should carefully consider their investment decisions and do their own research before investing in this stock.

Medicamen Biotech, a microcap pharmaceutical company, has recently seen a dip in its stock price, touching a 52-week low on March 5th, 2024. According to MarketsMOJO, a leading stock analysis platform, the stock has been given a 'Sell' call.

The current price of Medicamen Biotech is 0.99% away from its 52-week low of Rs 470.3. The stock has also underperformed the sector by -0.85% in today's trading session. In the last 3 days, the stock has been on a consecutive downward trend, with a fall of -3.31% in returns.

Furthermore, Medicamen Biotech is currently trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend in the stock.

In comparison to the Sensex, Medicamen Biotech's performance in the last year has been -28.36%, while the Sensex has seen a growth of 23.06%. This shows a significant underperformance by the company in the market.

As a microcap company in the pharmaceutical industry, Medicamen Biotech's stock price may be more volatile compared to larger companies. Investors should carefully consider their investment decisions and do their own research before making any decisions regarding this stock.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News